NCT06520982

Brief Summary

Our goal is to enhance our understanding of early vascular adaptations in aging women with an emphasis on the sympathetic nervous system.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
64

participants targeted

Target at P75+ for early_phase_1

Timeline
26mo left

Started Sep 2024

Longer than P75 for early_phase_1

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress43%
Sep 2024Jun 2028

First Submitted

Initial submission to the registry

July 22, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 25, 2024

Completed
2 months until next milestone

Study Start

First participant enrolled

September 20, 2024

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2028

Last Updated

November 26, 2025

Status Verified

November 1, 2025

Enrollment Period

2.8 years

First QC Date

July 22, 2024

Last Update Submit

November 20, 2025

Conditions

WomenSympathetic Nervous SystemAgingBlood Flow

Outcome Measures

Primary Outcomes (1)

  • Magnitude of forearm blood flow

    Change from baseline during infusion

Study Arms (1)

Women

OTHER

Women will be 18-70 years of age

Drug: NorepinephrineDrug: IsoproterenolDrug: AcetylcholineDrug: NitroprussideDrug: Estrogen

Interventions

NorepinephrineDRUG

Infused intra-arterially in a dose-response fashion

Women
IsoproterenolDRUG

Infused intra-arterially in a dose-response fashion

Women
AcetylcholineDRUG

Infused intra-arterially in a dose-response fashion

Women
NitroprussideDRUG

Infused intra-arterially in a dose-response fashion

Women
EstrogenDRUG

Infused intra-arterially

Women

Eligibility Criteria

Age18 Years - 70 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Assigned female at birth (AFAB)
  • years of age

You may not qualify if:

  • Assigned male at birth (AMAB)
  • Pregnancy, breastfeeding
  • Body mass index ≥30 kg/m2
  • Taking medications known to affect metabolic, autonomic, and/or respiratory function
  • Oral hormonal contraception in last 6 month
  • History of hormone replacement therapy
  • History of hyster- or oophor-ectomy
  • Current smoking/Nicotine use
  • Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy
  • Chronic disease
  • Blood pressure ≥140/90 mmHg
  • Communication barriers

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Missouri-Columbia

Columbia, Missouri, 65211, United States

RECRUITING

MeSH Terms

Interventions

NorepinephrineIsoproterenolAcetylcholineNitroprussideEstrogens

Intervention Hierarchy (Ancestors)

EthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesBiogenic MonoaminesBiogenic AminesCatecholaminesCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsFerricyanidesCyanidesAnionsIonsElectrolytesInorganic ChemicalsFerric CompoundsIron CompoundsHydrogen CyanideNitrogen CompoundsHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and Uses

Central Study Contacts

Jacqueline K Limberg

CONTACT

573-882-2420limbergj@missouri.edu

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

July 22, 2024

First Posted

July 25, 2024

Study Start

September 20, 2024

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

June 30, 2028

Last Updated

November 26, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations

US(1)